All In Biotech

Drug Trial Radar · NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,410 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,410

Planned (sponsor's estimate)

Start

Jan 6, 2026

Primary completion

Feb 27, 2029

Study completion Aug 26, 2032

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC. * Is not a candidate for complete surgical resection or curative chemoradiotherapy. * Do not have known actionable genomic alterations * Be treatment naïve for advanced or metastatic disease Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion: * Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor. * Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor. Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects. The study will include regular visits for: * Treatment and health checks: while participant continues receiving treatment. * Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.

Conditions

  • Advanced Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Non-Small-Cell Lung (NSCLC)
  • Metastatic Non Small Cell Lung Cancer
  • Lung Cancer

Interventions

  • PF-08634404Biological

    Solution for infusion

  • PembrolizumabBiological

    Injection for IV use

  • Chemotherapy Regimen 1Drug

    Injection for IV use

  • Chemotherapy Regimen 2Drug

    Injection for IV use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Approximately 39 months
  2. Progression Free Survival (PFS) assessed by blinded independent central review (BICR)Time frame: Approximately 32 months

Locations

484 sites in 20 countries. Site status is shown where the registry gives one.

  • Pioneer Research Center

    Bullhead City, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Chandler, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Gilbert, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Glendale, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Goodyear, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Mesa, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Phoenix, Arizona · Recruiting

  • Ironwood Cancer & Research Centers

    Scottsdale, Arizona · Recruiting

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • Oncura Health - Anaheim

    Anaheim, California · Recruiting

  • Memorial Care Orange Coast Medical Center Attn

    Fountain Valley, California · Recruiting

  • MemorialCare Orange Coast Medical Center

    Fountain Valley, California · Recruiting

  • OC Blood and Cancer Care

    Fountain Valley, California · Recruiting

  • Oncura Health - Fountain Valley

    Fountain Valley, California · Recruiting

  • Oncura Health - Corporate (Central IDS & Regulatory Only)

    Glendale, California · Recruiting

  • Memorial Care Saddleback Medical Center Attn

    Laguna Hills, California · Recruiting

  • MemorialCare Saddleback Medical Center

    Laguna Hills, California · Recruiting

  • Stockton Hematology Oncology Medical Group

    Lodi, California · Recruiting

  • Memorial Care Long Beach Medical Center

    Long Beach, California · Recruiting

  • Cancer and Blood Research Center, LLC (Storage)

    Los Alamitos, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • Oncura Health - Good Samaritan

    Los Angeles, California · Recruiting

  • California Research Institute

    Los Angeles, California · Recruiting

  • Stockton Hematology Oncology Medical Group

    Manteca, California · Recruiting

  • Stockton Hematology Oncology Medical Group

    Modesto, California · Recruiting

  • Oncura Health - Riverside

    Riverside, California · Recruiting

  • Roseville Medical Plaza Care Center

    Roseville, California · Not yet recruiting

  • Sutter Medical Center, Sacramento Infusion Center at Roseville

    Roseville, California · Not yet recruiting

  • Sutter Roseville Medical Center

    Roseville, California · Not yet recruiting

  • Sansum Clinic

    Santa Barbara, California · Recruiting

  • Sansum Clinic

    Solvang, California · Recruiting

  • Stockton Hematology Oncology Group

    Stockton, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Torrance, California · Recruiting

  • Stockton Hematology Oncology Medical Group

    Tracy, California · Recruiting

  • Oncura Health - Valley Presbyterian

    Van Nuys, California · Recruiting

  • Florida Cancer Specialists

    Bonita Springs, Florida · Recruiting

  • Florida Cancer Specialists

    Bradenton, Florida · Recruiting

Showing 40 of 484 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.